يعرض 1 - 20 نتائج من 75 نتيجة بحث عن '"Vynnychenko, I"', وقت الاستعلام: 0.52s تنقيح النتائج
  1. 1
    Academic Journal
  2. 2
  3. 3
    Academic Journal

    المصدر: Bukovinian Medical Herald; Vol. 17 No. 4 (68) (2013); 179-183 ; Буковинский медицинский вестник; Том 17 № 4 (68) (2013); 179-183 ; Буковинський медичний вісник; Том 17 № 4 (68) (2013); 179-183 ; 2413-0737 ; 1684-7903

    وصف الملف: application/pdf

  4. 4
  5. 5
    Conference

    المساهمون: Vanderbilt-Ingram Cancer Center, Nashville, TN

    Relation: https://doi.org/10.1200/JCO.2023.41.17_suppl.LBA4501; Rini BI, Plimack ER, Stus V, Gafanov R, Waddell T, Nosov D, et al. Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426. Journal of Clinical Oncology. 2023 Jun;41(17). PubMed PMID: WOS:001043181100025.; http://hdl.handle.net/10541/626581; Journal of Clinical Oncology

  6. 6
    Academic Journal

    المساهمون: R.L. Ferri, R. Haddad, C. Even, M. Tahara, M. Dvorkin, T.E. Ciuleanu, P.M. Clement, R. Mesia, S. Kutukova, L. Zholudeva, A. Daste, J. Caballero-Daroqui, B. Keam, I. Vynnychenko, C. Lafond, J. Shetty, H. Mann, J. Fan, S. Wildsmith, N. Morsli, J. Fayette, L. Licitra

    Relation: info:eu-repo/semantics/altIdentifier/pmid/32294530; info:eu-repo/semantics/altIdentifier/wos/WOS:000540695500017; volume:31; issue:7; firstpage:942; lastpage:950; numberofpages:9; journal:ANNALS OF ONCOLOGY; http://hdl.handle.net/2434/730558; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85084237800

  7. 7
    Academic Journal
  8. 8
    Academic Journal
  9. 9
    Academic Journal

    المساهمون: Fox Chase Cancer Center, Philadelphia, PA, USA.

    Relation: https://dx.doi.org/10.1016/j.eururo.2023.06.006; Plimack ER, Powles T, Stus V, Gafanov R, Nosov D, Waddell T, et al. Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study. Eur Urol. 2023 Jul 25. PubMed PMID: 37500340. Epub 2023/07/28. eng.; http://hdl.handle.net/10541/626481; European Urology

  10. 10
    Conference

    المساهمون: Barts Health NHS Trust and the Royal Free NHS Foundation Trust, Barts Cancer Institute, and Queen Mary University of London, London

    Relation: https://dx.doi.org/10.1200/JCO.2022.40.16_suppl.4513; Powles T, Plimack ER, Stus V, Waddell T, Gafanov R, Pouliot F, et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Analysis of progression after first subsequent therapy in KEYNOTE-426. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301334.; http://hdl.handle.net/10541/625803; Journal of Clinical Oncology

  11. 11
    Academic Journal
  12. 12
    Academic Journal
  13. 13
    Academic Journal

    مصطلحات موضوعية: Oncology

    وصف الملف: text

    Relation: http://repo.dma.dp.ua/7387/1/cancers-14-01168-v2.pdf; Shah, M.A. and Udrea, A.A. and Bondarenko, I. and Mansoor, W. and Sánchez, R.G. and Sarosiek, T. and Bozzarelli, S. and Schenker, M. and Gomez-Martin, C. and Morgan, C. and Özgüroglu, M. and Pikiel, J. and Kalofonos, H.P. and Wojcik, E. and Buchler, T. and Swinson, D. and Cicin, I. and Joseph, M. and Vynnychenko, I. and Luft, A.V. and Enzinger, P.C. and Salek, T. and Papandreou, C. and Tournigand, C. and Maiello, E. and Wei, R. and Ferry, D. and Gao, L. and Oliveira, J.M. and Ajani, J.A. (2022) Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies. Cancers, Vol.14 (iss. 5). p. 1168. ISSN 2072-6694

  14. 14
    Academic Journal

    المساهمون: Department of Urology, Eberhard Karls University of Tübingen, Tübingen, Germany

    Relation: https://dx.doi.org/10.1016/j.eururo.2022.06.009; Bedke J, Rini BI, Plimack ER, Stus V, Gafanov R, Waddell T, et al. Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma. Eur Urol. 2022 Jul 14. PubMed PMID: 35843776. Epub 2022/07/18. eng.; http://hdl.handle.net/10541/625435; European Urology

  15. 15
    Academic Journal

    المساهمون: Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil.

    Relation: https://dx.doi.org/10.1016/j.jtho.2022.09.223; de Castro G, Jr., Rizvi NA, Schmid P, Syrigos K, Martin C, Yamamoto N, et al. NEPTUNE: Phase III Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2022 Oct 11. PubMed PMID: 36240972. Epub 2022/10/15. eng.; http://hdl.handle.net/10541/625720; Journal of Thoracic Oncology

  16. 16
    Conference

    المساهمون: Vanderbilt-Ingram Cancer Center, Nashville, TN

    Relation: https://dx.doi.org/10.1200/JCO.2021.39.15_suppl.4500; Rini BI, Plimack ER, Stus V, Waddell T, Gafanov R, Pouliot F, et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426. Vol. 39, Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2021. p. 4500–4500.; http://hdl.handle.net/10541/624890; Journal of Clinical Oncology

  17. 17
  18. 18
  19. 19
  20. 20